Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of vegf monoclonal antibody combined with nano-paclitaxel in the preparation of drugs for the treatment of cancerous abdominal adhesions

A paclitaxel compound and paclitaxel technology, which are applied in the field of VEGF monoclonal antibody combined with nano-paclitaxel composition, can solve the problems of multiple complications, poor curative effect, increased mortality, etc., and achieve the effect of obvious symptom improvement and less toxic and side effects

Active Publication Date: 2021-02-05
杜楠
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Sunitinib (VEGFR-2 antagonist) can significantly reduce adhesion formation in mouse models, suggesting that anti-VEGF antibodies play a pivotal role in the treatment of peritoneal adhesions, but currently only VEGF monoclonal antibodies are used to treat cancerous peritoneal adhesions Still worse, and intravenous VEGF mAbs were associated with more complications and increased mortality, including bleeding (23.5%) and gastrointestinal perforation (7.1%)
[0004] As an anti-cancer drug, paclitaxel has obvious anti-tumor and anti-cancer effects in ovarian cancer, and has also shown excellent anti-tumor activity in a wide range of tumor models, but there is no report that it has the effect of anti-abdominal adhesions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of vegf monoclonal antibody combined with nano-paclitaxel in the preparation of drugs for the treatment of cancerous abdominal adhesions
  • Application of vegf monoclonal antibody combined with nano-paclitaxel in the preparation of drugs for the treatment of cancerous abdominal adhesions
  • Application of vegf monoclonal antibody combined with nano-paclitaxel in the preparation of drugs for the treatment of cancerous abdominal adhesions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 The therapeutic effect of VEGF monoclonal antibody combined with nano-paclitaxel on postoperative abdominal adhesions in mice

[0021] 1.1 Animals: Kunming mice, half male and half male

[0022] 1.2 Establishment of abdominal injury model

[0023] Animals were weighed before the operation, and pentobarbital sodium was given according to the dosage of 38 mg / kg. After complete anesthesia, under aseptic conditions, the abdominal incision was made in the middle of the lower abdomen. The sides of the intestinal canal were repeatedly rubbed with gauze 30 times, and the parietal peritoneum on the right side of the midline was repeatedly clamped with hemostatic forceps 30 times, and then the peritoneum was sutured with absorbable sutures, and finally the therapeutic drugs were slowly injected into the abdominal cavity before the sutures were ligated , and then ligated and sutured, closing the abdomen layer by layer. After fasting for 12 hours, the rats were fed in s...

Embodiment 2

[0033] Example 2 The therapeutic effect of VEGF monoclonal antibody formed by different VEGF monoclonal antibodies combined with nano-paclitaxel on postoperative abdominal adhesions in mice

[0034] The experimental animals used in this example, the adhesion evaluation criteria and the establishment of the abdominal cavity injury model are the same as those in Example 1.

[0035] 2.1 Grouping situation

[0036] 72 Kunming mice were randomly selected into 6 groups, 12 in each group, half male and half female. The treatment drug of test group 1 was bevacizumab combined with nano-paclitaxel; the treatment drug of test group 2 was ranibizumab combined with nano-paclitaxel; test 3 The treatment drug of group 4 was sunitinib combined with nano-paclitaxel; the drug of test group 4 was ranibizumab combined with nano-paclitaxel; the drug of test group 5 was pegatanib combined with nano-paclitaxel; the drug of test group 6 was VEGF rabbit IgG The weight ratio of anti-combined nano-pacl...

Embodiment 3

[0042] Example 3 Therapeutic effect of VEGF monoclonal antibody combined with nano-paclitaxel prepared from different weight ratios of VEGF monoclonal antibody and nano-paclitaxel on postoperative abdominal adhesions in mice

[0043]The experimental animals used in this example, the adhesion evaluation criteria and the establishment of the abdominal cavity injury model are the same as those in Example 1.

[0044] 3.1 Grouping situation

[0045] 80 Kunming mice were randomly selected into 8 groups, 10 in each group, half male and half male, and ranibizumab was combined with nano-paclitaxel to investigate the therapeutic effect of the compound obtained with different ratios of the two raw materials on abdominal adhesions. The drugs were diluted with 150mmol / L normal saline according to the volume of 1:100 before the test.

[0046] 3.2 Test results

[0047] Table 3 Effects of VEGF monoclonal antibody and nano-paclitaxel in different weight ratios on the therapeutic effect of VE...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of VEGF monoclonal antibody combined with nano-paclitaxel in the preparation of drugs for the treatment of cancerous abdominal adhesions and a composition of VEGF monoclonal antibody combined with nano-paclitaxel. The VEGF monoclonal antibody and nano-paclitaxel are combined to form a complex, which can be used in the treatment of cancerous abdominal adhesions. Abdominal adhesions have unexpected technical effects. Compared with the treatment of VEGF monoclonal antibody alone, the symptoms of abdominal adhesions and intestinal obstruction can be improved more obviously, and the toxic and side effects are less. In addition, the use of chitosan nano-encapsulated VEGF monoclonal antibody combined with nano-paclitaxel can make the duration of action longer and can regulate the time and intensity of action. While the curative effect is further enhanced, toxic side effects are further reduced, and the probability of complications occurs.

Description

technical field [0001] The invention belongs to the application field of pharmaceutical preparations, and particularly relates to the application of VEGF monoclonal antibody combined with nano-paclitaxel in the preparation of drugs for treating cancerous peritoneal adhesions and a composition of VEGF monoclonal antibody combined with nano-paclitaxel. Background technique [0002] The treatment of intra-abdominal adhesions has always been an important unsolved problem for clinicians. However, until now there is no standard treatment plan. According to the Mate analysis of foreign experimental studies and clinical observations in recent years, there is no surgical method that can completely prevent the formation of abdominal adhesions, and it is widely used in clinical practice. In recent years, many scholars have made great progress in the study of drugs to control and improve intra-abdominal adhesions due to surgical factors, such as drugs to reduce inflammation (non-steroid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/51A61K47/36A61K39/395A61K31/337A61P35/00A61P41/00
CPCA61K9/0019A61K9/5161A61K31/337A61K39/3955A61K2300/00
Inventor 杜楠
Owner 杜楠
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com